Fertility and sterility · 2011
Medical history screening for thrombophilic risk: is this adequate?
Оценочное исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Eggert-Kruse Waltraud, Ziegler Andrea, Horlbeck Sandra, Strowitzki Thomas
Аннотация
OBJECTIVE: To evaluate the reliability of medical history taken before hormonal medication administration to identify women with an increased risk for thromboembolic events detected by laboratory screening.
DESIGN: Prospective study.
SETTING: Outpatient endocrine clinic of a university-based hospital.
PATIENT(S): Four hundred forty-three consecutive women (median age 49 years) who presented with endocrine disorders.
INTERVENTION(S): None.
MAIN OUTCOME MEASURE(S): Parallel screening, on first visit, with a complete medical history, and same-day laboratory screening for thromboembolic risk. Laboratory examination in a two-step procedure with a standard assay and confirmation by genotyping on the second visit.
RESULT(S): A total of 13.8% (61/443) patients with an abnormal activated protein C (APC) resistance test were identified. Second blood samples revealed a prevalence of factor V (Leiden) heterozygosity in 10.9% (homozygosity in 0.2%). There was a significantly higher prevalence of thrombotic events in a first degree relative of patients with APC resistance (in 18.3%) compared with women with a normal test outcome (in 7.8%). However, medical history (personal and family history) was negative concerning hints for thromboembolic events in more than 80% of patients with a laboratory risk profile for thromboembolic morbidity. No association of APC and factor V testing with the patients' gynecological/obstetric history (e.g., live birth rate, miscarriages) was observed.
CONCLUSION(S): Medical history alone may be inadequate to identify all patients at risk for thromboembolic complications with hormonal treatment.
DESIGN: Prospective study.
SETTING: Outpatient endocrine clinic of a university-based hospital.
PATIENT(S): Four hundred forty-three consecutive women (median age 49 years) who presented with endocrine disorders.
INTERVENTION(S): None.
MAIN OUTCOME MEASURE(S): Parallel screening, on first visit, with a complete medical history, and same-day laboratory screening for thromboembolic risk. Laboratory examination in a two-step procedure with a standard assay and confirmation by genotyping on the second visit.
RESULT(S): A total of 13.8% (61/443) patients with an abnormal activated protein C (APC) resistance test were identified. Second blood samples revealed a prevalence of factor V (Leiden) heterozygosity in 10.9% (homozygosity in 0.2%). There was a significantly higher prevalence of thrombotic events in a first degree relative of patients with APC resistance (in 18.3%) compared with women with a normal test outcome (in 7.8%). However, medical history (personal and family history) was negative concerning hints for thromboembolic events in more than 80% of patients with a laboratory risk profile for thromboembolic morbidity. No association of APC and factor V testing with the patients' gynecological/obstetric history (e.g., live birth rate, miscarriages) was observed.
CONCLUSION(S): Medical history alone may be inadequate to identify all patients at risk for thromboembolic complications with hormonal treatment.